Literature DB >> 26503985

Pivotal role of miR-448 in the development of ROS-induced cardiomyopathy.

Sergii Kyrychenko1, Viktoriia Kyrychenko1, Myriam A Badr1, Yoshiyuki Ikeda2, Junichi Sadoshima2, Natalia Shirokova3.   

Abstract

AIMS: Nicotinamide adenine dinucleotide oxidases (NOXs) are important contributors to cellular oxidative stress in the cardiovascular system. The NOX2 isoform is upregulated in numerous disorders, including dystrophic cardiomyopathy, where it drives the progression of the disease. However, mechanisms underlying NOX2 overexpression are still unknown. We investigated the role of microRNAs (miRs) in the regulation of NOX2 expression. METHODS AND
RESULTS: Duchenne muscular dystrophy (DMD) was used as a model of cardiomyopathy. After screening with miRNA target prediction databases and following qRT-PCR analysis, we found drastic downregulation of miR-448-3p in hearts of mdx mice, an animal model of DMD. The downregulation correlated with overexpression of the Ncf1 gene, encoding the NOX2 regulatory subunit p47(phox). Specificity of Ncf1 targeting by miR-448-3p was validated by luciferase reporter assay. Silencing of miR-448-3p in wild-type mice had a dramatic effect on cellular and functional properties of cardiac muscle as assessed by western blotting, qRT-PCR, confocal imaging, echocardiography, and histology. Acute treatment of mice with LNA-miR-448 inhibitors led to increased Ncf1 expression, abnormally elevated reactive oxygen species (ROS) production and exacerbated Ca(2+) signalling in cardiomyocytes, reminiscent of features previously observed in dystrophic cardiac cells. In addition, chronic inhibition of miR-448-3p resulted in dilated cardiomyopathy and arrhythmia, hallmarks of dystrophic cardiomyopathy.
CONCLUSIONS: Our studies suggest that downregulation of miR-448-3p leads to the increase in the expression of Ncf1 gene and p47(phox) protein, as well as to the substantial increase in NOX2-derived ROS production. Cellular oxidative stress subsequently triggers events that finally culminate in cardiac tissue damage and development of cardiomyopathy. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiomyopathy; Dystrophin; NOX; Oxidative stress; microRNA

Mesh:

Substances:

Year:  2015        PMID: 26503985      PMCID: PMC4648202          DOI: 10.1093/cvr/cvv238

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  37 in total

Review 1.  Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?

Authors:  Esther E Creemers; Anke J Tijsen; Yigal M Pinto
Journal:  Circ Res       Date:  2012-02-03       Impact factor: 17.367

Review 2.  Differential expression of microRNAs in different disease states.

Authors:  Maha Abdellatif
Journal:  Circ Res       Date:  2012-02-17       Impact factor: 17.367

3.  Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy.

Authors:  Satyam Sarma; Na Li; Ralph J van Oort; Corey Reynolds; Darlene G Skapura; Xander H T Wehrens
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 4.  NADPH oxidases and cardiac remodelling.

Authors:  Adam Nabeebaccus; Min Zhang; Ajay M Shah
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

5.  X-ROS signaling: rapid mechano-chemo transduction in heart.

Authors:  Benjamin L Prosser; Christopher W Ward; W J Lederer
Journal:  Science       Date:  2011-09-09       Impact factor: 47.728

6.  miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy.

Authors:  Davide Cacchiarelli; Tania Incitti; Julie Martone; Marcella Cesana; Valentina Cazzella; Tiziana Santini; Olga Sthandier; Irene Bozzoni
Journal:  EMBO Rep       Date:  2011-01-07       Impact factor: 8.807

Review 7.  MicroRNAs add a new dimension to cardiovascular disease.

Authors:  Eric M Small; Robert J A Frost; Eric N Olson
Journal:  Circulation       Date:  2010-03-02       Impact factor: 29.690

8.  Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.

Authors:  Q-Q Li; Z-Q Chen; X-X Cao; J-D Xu; J-W Xu; Y-Y Chen; W-J Wang; Q Chen; F Tang; X-P Liu; Z-D Xu
Journal:  Cell Death Differ       Date:  2010-08-27       Impact factor: 15.828

9.  Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy.

Authors:  Jérémy Fauconnier; Jérôme Thireau; Steven Reiken; Cécile Cassan; Sylvain Richard; Stefan Matecki; Andrew R Marks; Alain Lacampagne
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Atypical transcription of microRNA gene fragments.

Authors:  Jin Song Gao; Yingjie Zhang; Ming Li; Lynne D Tucker; Jason T Machan; Peter Quesenberry; Isidore Rigoutsos; Bharat Ramratnam
Journal:  Nucleic Acids Res       Date:  2010-01-21       Impact factor: 16.971

View more
  20 in total

1.  MiR-200a inhibits cell proliferation and EMT by down-regulating the ASPH expression levels and affecting ERK and PI3K/Akt pathways in human hepatoma cells.

Authors:  Wei-Feng Yao; Jun-Wei Liu; Dong-Sheng Huang
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

2.  An integrative approach to investigate the association among high-sensitive C-reactive protein, body fat mass distribution, and other cardiometabolic risk factors in young healthy women.

Authors:  Bin Wu; Jingshan Huang; Lihua Zhang; Mohan Vamsi Kasukurthi; Fangwan Huang; Jiang Bian; Keisuke Fukuo; Tsutomu Kazumi
Journal:  Methods       Date:  2018-04-24       Impact factor: 3.608

Review 3.  Regulatory pathways and drugs associated with ferroptosis in tumors.

Authors:  Dan Wang; Le Tang; Yijie Zhang; Guili Ge; Xianjie Jiang; Yongzhen Mo; Pan Wu; Xiangying Deng; Lvyuan Li; Sicheng Zuo; Qijia Yan; Shanshan Zhang; Fuyan Wang; Lei Shi; Xiayu Li; Bo Xiang; Ming Zhou; Qianjin Liao; Can Guo; Zhaoyang Zeng; Wei Xiong; Zhaojian Gong
Journal:  Cell Death Dis       Date:  2022-06-10       Impact factor: 9.685

Review 4.  Dystrophic Cardiomyopathy: Complex Pathobiological Processes to Generate Clinical Phenotype.

Authors:  Takeshi Tsuda; Kristi K Fitzgerald
Journal:  J Cardiovasc Dev Dis       Date:  2017-09-08

Review 5.  MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases.

Authors:  Montserrat Climent; Giacomo Viggiani; Ya-Wen Chen; Gerald Coulis; Alessandra Castaldi
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

Review 6.  MicroRNAs and obesity-induced endothelial dysfunction: key paradigms in molecular therapy.

Authors:  Karima Ait-Aissa; Quynh My Nguyen; Mohanad Gabani; Adam Kassan; Santosh Kumar; Soo-Kyoung Choi; Alexis A Gonzalez; Tahsin Khataei; Amal M Sahyoun; Cheng Chen; Modar Kassan
Journal:  Cardiovasc Diabetol       Date:  2020-09-09       Impact factor: 9.951

Review 7.  Ferroptosis and Cancer: Mitochondria Meet the "Iron Maiden" Cell Death.

Authors:  Anna Martina Battaglia; Roberta Chirillo; Ilenia Aversa; Alessandro Sacco; Francesco Costanzo; Flavia Biamonte
Journal:  Cells       Date:  2020-06-20       Impact factor: 6.600

8.  A homozygous nonsense mutation in DCBLD2 is a candidate cause of developmental delay, dysmorphic features and restrictive cardiomyopathy.

Authors:  Kheloud M Alhamoudi; Tlili Barhoumi; Hamad Al-Eidi; Abdulaziz Asiri; Marwan Nashabat; Manal Alaamery; Masheal Alharbi; Yazeid Alhaidan; Brahim Tabarki; Muhammad Umair; Majid Alfadhel
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

9.  Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy.

Authors:  Meng Jiao; Hong-Zhao You; Xin-Ying Yang; Hui Yuan; Yu-Lin Li; Wen-Xian Liu; Mei Jin; Jie Du
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

10.  miR‑448 targets Rab2B and is pivotal in the suppression of pancreatic cancer.

Authors:  Jing Jin; Yingsheng Wu; Dongkai Zhou; Qiang Sun; Weilin Wang
Journal:  Oncol Rep       Date:  2018-07-12       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.